Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

By Twesha Dikshit (Reuters) -European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo ...

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares. Kelly Clarkson's ex-husband Brandon Blackstock ...

Shares rose for a second day, in a rally sparked by rival Eli Lilly (LLY) reporting less-than-stellar trial results for an ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...